Demant A/S (OTCMKTS:WILYY) Sets New 1-Year High – What’s Next?

Demant A/S Unsponsored ADR (OTCMKTS:WILYY)’s stock price reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as $21.87 and last traded at $21.87, with a volume of 451 shares changing hands. The stock had previously closed at $19.25.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on WILYY shares. Zacks Research upgraded shares of Demant A/S to a “hold” rating in a report on Friday, June 26th. Sanford C. Bernstein downgraded Demant A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 17th. Morgan Stanley upgraded shares of Demant A/S from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, June 23rd. Finally, UBS Group downgraded Demant A/S from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy”.

Demant A/S Stock Up 5.9%

The business’s 50 day moving average price is $20.06 and its 200-day moving average price is $17.19. The company has a debt-to-equity ratio of 1.65, a quick ratio of 1.00 and a current ratio of 1.36.

About Demant A/S

Demant A/S is a Denmark-based global hearing health care company specializing in the development, manufacture and distribution of hearing solutions and audiological diagnostic instruments. The company’s flagship brands include Oticon, Bernafon and Sonic, which offer a range of hearing aids designed to address various levels of hearing loss. In addition to personal hearing devices, Demant provides diagnostic equipment such as audiometers and tympanometers, supporting hearing care professionals in accurate assessment and fitting of hearing solutions.

Beyond hearing aids and diagnostics, Demant’s product portfolio extends to hearing implants—cochlear and bone-anchored systems—through its Oticon Medical division.